191 related articles for article (PubMed ID: 22157599)
21. In-vivo metabolism of VLDL-apolipoprotein-B, -CIII and -E in normolipidemic subjects.
Dinkel RE; Barrett PH; Demant T; Parhofer KG
Nutr Metab Cardiovasc Dis; 2006 Apr; 16(3):215-21. PubMed ID: 16580589
[TBL] [Abstract][Full Text] [Related]
22. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
23. Lifibrol as a model compound for a novel lipid-lowering mechanism of action.
Berthold HK; Sudhop T; von Bergmann K; Gouni-Berthold I
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):364-72. PubMed ID: 20693157
[TBL] [Abstract][Full Text] [Related]
24. Beneficial effects of atorvastatin on sd LDL and LDL phenotype B in statin-naive patients and patients previously treated with simvastatin or pravastatin.
Baldassarre S; Scruel O; Deckelbaum RJ; Dupont IE; Ducobu J; Carpentier YA
Int J Cardiol; 2005 Oct; 104(3):338-45. PubMed ID: 16186066
[TBL] [Abstract][Full Text] [Related]
25. Lifibrol enhances the low density lipoprotein apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia.
Winkler K; Schäfer JR; Klima B; Nuber C; Sattler A; Friedrich I; Köster W; Steinmetz A; Wieland H; März W
Atherosclerosis; 1999 May; 144(1):167-75. PubMed ID: 10381290
[TBL] [Abstract][Full Text] [Related]
26. Lipoprotein kinetics in male hemodialysis patients treated with atorvastatin.
Schwaiger JP; Nakada Y; Berberich R; Ikewaki K; Dieplinger B; Zitt E; Neyer U; Salmhofer H; Kronenberg F; Koenig P; Dieplinger H
Clin J Am Soc Nephrol; 2013 Aug; 8(8):1319-26. PubMed ID: 23599405
[TBL] [Abstract][Full Text] [Related]
27. Effect of low-density lipoprotein apheresis on kinetics of apolipoprotein B in heterozygous familial hypercholesterolemia.
Maugeais C; Ouguerram K; Frénais R; Maugère P; Charbonnel B; Magot T; Krempf M
J Clin Endocrinol Metab; 2001 Apr; 86(4):1679-86. PubMed ID: 11297603
[TBL] [Abstract][Full Text] [Related]
28. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
Aguilar-Salinas CA; Hugh P; Barrett R; Pulai J; Zhu XL; Schonfeld G
Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):72-82. PubMed ID: 9012640
[TBL] [Abstract][Full Text] [Related]
29. Effect of a statin on hepatic apolipoprotein B-100 secretion and plasma campesterol levels in the metabolic syndrome.
Watts GF; Chan DC; Barrett PH; O'Neill FH; Thompson GR
Int J Obes Relat Metab Disord; 2003 Jul; 27(7):862-5. PubMed ID: 12821974
[TBL] [Abstract][Full Text] [Related]
30. Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia.
Jones C; Garuti R; Michaely P; Li WP; Maeda N; Cohen JC; Herz J; Hobbs HH
J Clin Invest; 2007 Jan; 117(1):165-74. PubMed ID: 17200716
[TBL] [Abstract][Full Text] [Related]
31. ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm.
Fisher WR; Zech LA; Stacpoole PW
Arterioscler Thromb; 1994 Apr; 14(4):501-10. PubMed ID: 8148348
[TBL] [Abstract][Full Text] [Related]
32. Metabolic basis of hyperapobetalipoproteinemia. Turnover of apolipoprotein B in low density lipoprotein and its precursors and subfractions compared with normal and familial hypercholesterolemia.
Teng B; Sniderman AD; Soutar AK; Thompson GR
J Clin Invest; 1986 Mar; 77(3):663-72. PubMed ID: 3949973
[TBL] [Abstract][Full Text] [Related]
33. Determination of kinetic parameters of apolipoprotein B metabolism using amino acids labeled with stable isotopes.
Parhofer KG; Hugh P; Barrett R; Bier DM; Schonfeld G
J Lipid Res; 1991 Aug; 32(8):1311-23. PubMed ID: 1770313
[TBL] [Abstract][Full Text] [Related]
34. Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism.
Watts GF; Chan DC; Dent R; Somaratne R; Wasserman SM; Scott R; Burrows S; R Barrett PH
Circulation; 2017 Jan; 135(4):338-351. PubMed ID: 27941065
[TBL] [Abstract][Full Text] [Related]
35. Low-density lipoprotein-apolipoprotein B metabolism following apheresis: simulation studies of mass changes and tracer kinetics.
Barrett PH; Parhofer KG
Metabolism; 1998 Apr; 47(4):478-83. PubMed ID: 9550549
[TBL] [Abstract][Full Text] [Related]
36. Post-prandial remnant lipoprotein metabolism in autosomal recessive hypercholesterolaemia.
Tada H; Kawashiri MA; Tanaka A; Nakano T; Nakajima K; Inoue T; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
Eur J Clin Invest; 2012 Oct; 42(10):1094-9. PubMed ID: 22725843
[TBL] [Abstract][Full Text] [Related]
37. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins.
Ishigami M; Yamashita S; Sakai N; Hirano K; Hiraoka H; Nakamura T; Matsuzawa Y
Atherosclerosis; 2003 Jun; 168(2):359-66. PubMed ID: 12801620
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.
Ma L; Waldmann E; Ooi EMM; Chan DC; Barrett HPR; Watts GF; Parhofer KG
Eur J Clin Invest; 2019 Feb; 49(2):e13053. PubMed ID: 30447089
[TBL] [Abstract][Full Text] [Related]
39. The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification.
Fellin R; Arca M; Zuliani G; Calandra S; Bertolini S
Gene; 2015 Jan; 555(1):23-32. PubMed ID: 25225128
[TBL] [Abstract][Full Text] [Related]
40. Acute effects of low density lipoprotein apheresis on metabolic parameters of apolipoprotein B.
Parhofer KG; Barrett PH; Demant T; Schwandt P
J Lipid Res; 2000 Oct; 41(10):1596-603. PubMed ID: 11013301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
